Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...

Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

The company has multiple drugs in its pipeline that could generate billions in revenue.
Forbes

What GLP-1 Drugs Teach Us About Revolutionary Drug Development

Glucagon-like peptide agonists (GLP-1s, like Ozempic, Wegovy, and Mounjaro) have been hailed as breakthroughs. From statins to Viagra, occasionally a drug development breakthrough occurs that is ...
Seeking Alpha

Revolution Medicines: "Strong Buy" As Acquisition Prospects Continue To Circle

The last time I spoke about Revolution Medicines (RVMD) it was with respect to a Seeking Alpha article entitled "Revolution Should Be On Your Radar; 'Undruggable Targets' Now Potentially Druggable".